摘要
Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute espiratory syndrome-coronavirus-2 (SARS-CoV-2). The Oxford-AstraZeneca COVID-19 vaccine is based on an adenovirus vector and has been extensively used to prevent the COVID-19 infection or complications. Severe thrombotic adverse reactions caused by the AstraZeneca COVID-19 vaccine have been reported in several countries.1 Acute myocardial infarction (AMI) is an emergent cardiovascular disease and occurs mostly due to thrombus obstruction of the coronary artery caused by a rupture of atherosclerotic plaques. Herein, we report a case of a 60-year-old man with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) after receiving his first dose of the AstraZeneca vaccine.
原文 | 英語 |
---|---|
頁(從 - 到) | 417-420 |
頁數 | 4 |
期刊 | Acta Cardiologica Sinica |
卷 | 38 |
發行號 | 3 |
DOIs | |
出版狀態 | 已發佈 - 5月 2022 |
ASJC Scopus subject areas
- 心臟病學與心血管醫學